Trial Profile

IMPACT OF THERAPY INTENSIFICATION BY AN INTEGRASE INHIBITOR +/- CCR5 INHIBITOR ON THE LYMPHOID RESERVOIR FOR HIV-1 IN CHRONICALLY INFECTED PATIENTS

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; HIV protease inhibitors; Maraviroc; Ritonavir; RNA-directed DNA polymerase inhibitors
Indications HIV infections
Focus Therapeutic Use
Acronyms IntensVIH

Most Recent Events

16 Apr 2014 Trial status changed to completed as reported by ClinicalTrials.gov.
24 Jan 2013 Planned End Date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
06 Dec 2011 Planned end date changed from 1 Oct 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com